Holen Sie sich die Stockscreener-App
12.68
5.14%
0.62
Vorhandelsmarkt:
12.68
Schlusskurs vom Vortag:
$12.06
Offen:
$12.13
24-Stunden-Volumen:
411.33K
Relative Volume:
1.12
Marktkapitalisierung:
$454.64M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+37.53%
1M Leistung:
+69.29%
6M Leistung:
+189.50%
1J Leistung:
+183.67%
1-Tages-Spanne:
$12.03
$12.80
1-Wochen-Bereich:
$9.85
$12.80
52-Wochen-Spanne:
$2.88
$12.80
Bioage Labs Inc Stock (BIOA) Company Profile
Firmenname
Bioage Labs Inc
Sektor
Telefon
510-806-1445
Adresse
5885 HOLLIS STREET, EMERYVILLE
Vergleichen Sie BIOA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BIOA
Bioage Labs Inc
|
12.68 | 432.41M | 0 | 0 | 0 | 0.00 |
|
ZTS
Zoetis Inc
|
118.07 | 51.01B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.37 | 45.05B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.46 | 41.46B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
29.80 | 32.77B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
484.86 | 20.51B | 3.08B | 1.24B | 1.07B | 25.61 |
Bioage Labs Inc Stock (BIOA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-05 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2025-10-22 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-02-28 | Eingeleitet | William Blair | Mkt Perform |
| 2024-12-10 | Herabstufung | Morgan Stanley | Overweight → Underweight |
| 2024-12-09 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-12-09 | Herabstufung | Jefferies | Buy → Hold |
| 2024-10-21 | Eingeleitet | Citigroup | Buy |
| 2024-10-21 | Eingeleitet | Jefferies | Buy |
| 2024-10-21 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Bioage Labs Inc Aktie (BIOA) Neueste Nachrichten
Morgan Stanley Upgrades BioAge Labs (BIOA) - Nasdaq
BioAge Labs (BIOA) Competitors and Alternatives 2025 - MarketBeat
Volume Recap: How BioAge Labs Inc stock reacts to Fed rate cutsFed Meeting & Technical Pattern Recognition Alerts - BỘ NỘI VỤ
BioAge Labs CMO Paul D. Rubin Sells All Common Stock Holdings - TradingView
Officer Rubin Sells 68,897 ($701.9K) Of BioAge Labs Inc [BIOA] - TradingView
BioAge Labs stock rating upgraded by Morgan Stanley on promising BGE-102 data - Investing.com South Africa
How BioAge Labs Inc. stock reacts to Fed rate cutsShort Setup & Fast Gain Stock Trading Tips - Newser
BioAge’s NLRP3 inhibitor shows positive Phase 1 data in clinical trial - Investing.com Nigeria
Is BioAge Labs Inc. stock a safe haven assetQuarterly Earnings Summary & Safe Entry Zone Identification - Newser
Why BioAge Labs Inc. stock remains undervaluedCEO Change & Smart Money Movement Alerts - Newser
How BioAge Labs Inc. (Y7G) stock stacks up against competitorsInsider Selling & Daily Chart Pattern Signal Reports - Newser
Positive Developments and Promising Trials Bolster Buy Rating for BioAge Labs - TipRanks
Citi Maintains BioAge Labs(BIOA.US) With Buy Rating, Maintains Target Price $15 - 富途牛牛
Officer Rubin Files To Sell 68,897 Of BioAge Labs Inc [BIOA] - TradingView
Will BioAge Labs Inc. (Y7G) stock outperform global peersCEO Change & Safe Capital Investment Plans - Newser
Merger Talk: Is BioAge Labs Inc stock a safe haven assetPortfolio Growth Summary & Weekly Watchlist of Top Performers - BỘ NỘI VỤ
BioAge Labs BGE-102 Phase 1 Trial Shows Potential in Targeting Inflammation in Central Nervous System, Peripheral Tissues - marketscreener.com
BioAge Reports Positive Interim Phase 1 Data For BGE-102; Shares Rise - Nasdaq
BioAge Labs Announces Positive Phase 1 Trial Results - TipRanks
BioAge Announces Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor - markets.businessinsider.com
BioAge Labs, Inc. Announces Positive Interim Phase 1 Data for BGE-102 - TradingView
BioAge’s NLRP3 inhibitor shows positive Phase 1 data in clinical trial By Investing.com - Investing.com South Africa
Is BioAge Labs Inc. (Y7G) stock a buy before new product rolloutJuly 2025 Outlook & Long Hold Capital Preservation Plans - Newser
Is BioAge Labs Inc. (Y7G) stock bottoming after sell off2025 Major Catalysts & Daily Volume Surge Trade Alerts - Newser
BioAge Labs announces positive phase 1 trial results - MSN
Bioage Labs (BIOA) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Is BioAge Labs Inc. (Y7G) stock supported by free cash flowVolume Spike & Fast Moving Stock Watchlists - Newser
Jefferies Financial Group Inc. Buys Shares of 50,000 BioAge Labs, Inc. $BIOA - MarketBeat
What analysts say about BioAge Labs Inc Y7G stockFibonacci Extensions & Rapid Capital Trading Tips - earlytimes.in
Dhanalaxmi Roto Spinners Limited Stock Analysis Technical Signals for YEARCash Flow Trends & Invest With Confidence - earlytimes.in
BioAge Labs to Present at Piper Sandler 37th Annual Healthcare Conference - Sahm
BioAge Labs (NASDAQ: BIOA) plans Piper Sandler fireside chat and investor meetings Dec. 4 - Stock Titan
Recent uptick might appease BioAge Labs, Inc. (NASDAQ:BIOA) institutional owners after losing 55% over the past year - Yahoo Finance
Is BioAge Labs Inc a good long term investmentCapital Gains Strategies & Small Budget Portfolio Growth - earlytimes.in
BioAge stock craters 70% on obesity drug study halt (update) - MSN
Is BioAge Labs Inc. stock recession proofStop Loss & Free Weekly Watchlist of Top Performers - newser.com
Will BioAge Labs Inc. (Y7G) stock hit analyst forecastsBuy Signal & Expert Curated Trade Ideas - newser.com
BioAge Labs (BIOA) Price Target Increased by 20.83% to 9.86 - MSN
Is BioAge Labs Inc. (Y7G) stock a buy on weakness2025 Short Interest & Risk Adjusted Buy and Sell Alerts - newser.com
How interest rate cuts could boost BioAge Labs Inc. stock2025 Earnings Impact & Accurate Intraday Trading Signals - newser.com
Is BioAge Labs Inc. stock a buy before product launchesMarket Volume Report & Weekly Top Stock Performers List - newser.com
Finanzdaten der Bioage Labs Inc-Aktie (BIOA)
Es liegen keine Finanzdaten für Bioage Labs Inc (BIOA) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
4.87%
4.26%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):